8-K: DocGo Acquires Hicuity Health, Reports Q2 Results

DocGo Inc. announced a definitive agreement to acquire Hicuity Health, a virtual care provider, while reporting a net loss and decreased Q2 revenue, though excluding certain programs, revenue increased.

Summary

• DocGo Inc. has entered into a definitive agreement to acquire Hicuity Health, a virtual care provider specializing in Tele-ICU, Virtual Nursing, and Telemetry Monitoring.
• The acquisition consideration includes the assumption of Hicuity's existing indebtedness of approximately $52 million and equity in DocGo common stock for Hicuity's preferred shareholder.
• DocGo reported total revenue of $73.4 million for Q2 2026, a decrease from $80.4 million in Q2 2025, primarily due to the wind-down of migrant-related programs.
• Excluding migrant programs, total revenue increased by 19% year-over-year, and Mobile Health Services revenue (excluding migrant programs) grew 78%.
• The company reported a net loss of $18.0 million for Q2 2026, compared to a net loss of $13.3 million in Q2 2025.
• Adjusted EBITDA for Q2 2026 was ($6.3) million, a slight decrease from ($6.1) million in Q2 2025.
• Full-year 2026 revenue guidance has been narrowed to $305-$310 million, excluding Hicuity's contribution.
• Full-year 2026 adjusted EBITDA guidance has been widened to ($17-$22) million, from ($5-$10) million previously.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the reported net loss, decreased revenue year-over-year (though adjusted for specific programs), and a widened adjusted EBITDA guidance range. While the acquisition of Hicuity Health presents a strategic opportunity, the immediate financial implications and the ongoing losses temper the sentiment.

Positives

• Strategic acquisition of Hicuity Health, a virtual care provider, to enhance DocGo's healthcare delivery platform.
• Excluding migrant-related programs, total revenue increased 19% year-over-year.
• Mobile Health Services revenue, excluding migrant programs, increased 78% year-over-year, driven by organic growth and SteadyMD.
• Record volumes achieved across all major business lines, including US medical transportation (+15%), healthcare in the home (+26%), and virtual care & lab orders (+58%).
• Signed a new contract with a national health plan for care gap closure services in Pennsylvania.
• Launched mobile phlebotomy services in Southern Florida.
• Perceptive Advisors committed to providing up to $50 million in new debt financing.
• Company expects to exit the year at a profitable run rate and achieve positive adjusted EBITDA run rate by year-end 2026/early 2027.

Negatives

• Total revenue decreased to $73.4 million in Q2 2026 from $80.4 million in Q2 2025, primarily due to the wind-down of migrant-related programs.
• Net loss widened to $18.0 million in Q2 2026 from $13.3 million in Q2 2025.
• Adjusted EBITDA was ($6.3) million in Q2 2026, compared to ($6.1) million in Q2 2025.
• Full-year 2026 adjusted EBITDA guidance has been significantly widened to ($17-$22) million, indicating a less favorable outlook than previously projected.
• Cash and cash equivalents decreased to $48.1 million as of June 30, 2026, from $59.9 million as of March 31, 2026.
• Unrestricted cash and cash equivalents decreased to $25.2 million from $35.7 million over the same period.
• Hicuity's Series F preferred stockholders are the sole recipients of merger consideration, with other Hicuity shareholders and option/warrant holders receiving no consideration.

Risks

• The wind-down of migrant-related services significantly impacted revenue.
• The company's ability to continue as a going concern is mentioned in the forward-looking statements.
• Integration risks associated with the Hicuity Health acquisition.
• Potential for downward adjustment of Earnout Shares based on final determination of closing indebtedness and transaction expenses.
• Earnout Shares will be forfeited if vesting conditions (market capitalization threshold) are not met by the earnout expiration date.
• Reliance on government contracts and potential changes in government spending.
• Competition in the highly competitive healthcare transportation and mobile health services markets.
• Information technology system failures, network disruptions, cyber incidents, or unauthorized access to confidential information.

Future Outlook

Full-year 2026 revenue guidance is narrowed to $305-$310 million (excluding Hicuity). Full-year 2026 adjusted EBITDA guidance is widened to ($17-$22) million, with the company still expecting to exit the year at a profitable run rate and achieve positive adjusted EBITDA run rate by year-end 2026/early 2027.

Management Comments

• "The continued evolution of our company into the premier provider of virtual, remote, and in-home healthcare at any address took a major leap forward with our pending acquisition of virtual care provider Hicuity Health."
• "Hicuity brings technology-enabled acute and critical care telemedicine capabilities, serving a diverse portfolio of health systems across the United States. Integrating the power of Hicuitys offering helps us create one of the most innovative healthcare delivery platforms in the industry – a holistic tech-powered solution that enables us to match the right clinician with the right patient at the right time in the right setting."
• "This solidifies our companys unique position to bridge patient care across the entire continuum from the hospital to the home."
• "The pending acquisition of Hicuity represents not only a significant growth opportunity with numerous cost synergies, but will also create a combined entity with much greater financial liquidity."
• "Our cost cutting initiatives progressed during the quarter, with more than four million dollars of estimated annual costs removed from SG&A during the period while also achieving record volumes across all key business verticals."
• "We believe that the Company will achieve a positive adjusted EBITDA run rate as we exit the year and head into 2027."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the broader industry trend of consolidation and the integration of virtual and in-home care solutions to create more comprehensive and cost-effective healthcare delivery models. The move positions DocGo to compete more effectively by expanding its service offerings into higher-acuity virtual care.

Comparison to Industry Standards

• The adjusted EBITDA guidance of ($17-$22) million for FY2026 is a significant negative deviation from prior guidance of ($5-$10) million, suggesting challenges in achieving profitability targets compared to industry peers who may be demonstrating stronger cost control or revenue growth.
• The year-over-year revenue decline in Q2 2026, even when adjusted for specific program wind-downs, indicates a slower growth trajectory than some competitors in the rapidly expanding telehealth and home healthcare sectors.
• While DocGo aims for a positive adjusted EBITDA run rate by year-end, many established players in the virtual care space are already achieving consistent profitability, highlighting a gap in current performance.

Stakeholder Impact

• Shareholders: Potential dilution from stock consideration in the Hicuity acquisition, but also potential long-term value creation from expanded service offerings. The widened EBITDA guidance may negatively impact share price in the short term.
• Creditors: Assumption of Hicuity's $52 million debt by Ambulnz, with a new $50 million financing commitment from Perceptive Advisors, impacting the company's debt structure.
• Hicuity Health Shareholders: Series F preferred stockholders are the sole recipients of merger consideration; other shareholders receive nothing.
• Employees: Potential for integration-related changes and opportunities within the combined entity.

Next Steps

• Complete the acquisition of Hicuity Health.
• Integrate Hicuity Health's operations and technology into DocGo's platform.
• Continue to manage cost-cutting initiatives.
• Achieve a profitable run rate by the end of 2026.
• Host a conference call and webcast to discuss Q2 2026 results and the Hicuity acquisition.

Key Dates

Recommendation

The acquisition of Hicuity Health is strategically sound, expanding DocGo's capabilities in virtual care. However, the continued net losses, widening EBITDA guidance, and decrease in unrestricted cash warrant caution. The company's ability to execute the integration and achieve profitability remains a key concern. A 'hold' recommendation reflects the balance between strategic potential and current financial performance challenges.

Keywords

virtual care, merger, acquisition, telemedicine, mobile health, medical transportation, healthcare services, financial results